For men with metastatic castration-resistant prostate cancer (mCRPC), any new therapy that offers the chance of a higher response rate or longer survival compared with the standard of the care would be welcome.
The US Food and Drug Administration (FDA) recently approved two such drugs for use in men with mCRPC: the poly (ADP-ribose) polymerase (PARP) inhibitors rucaparib (Rubraca) and olaparib (LynParza).
Both drugs were approved for use in the treatment of men with advanced prostate cancer with deleterious germline and/or somatic BRCA mutations following treatment with androgen receptor–directed therapy and taxane-based chemotherapy.
But there was difference in the wording of the indication that was approved, as noted by Michael T. Schweizer, MD, and colleagues from the Fred Hutchinson Cancer Research Center and the University of Washington in Seattle, Washington, in a recent commentary published in the Journal of Clinical Oncology.
Olaparib received wider approval for treatment of “deleterious or